ME Therapeutics Holdings Inc. (METXF)

Market Cap	60.18M -13.8%
Revenue (ttm)	n/a
Net Income	-1.00M
EPS	-0.03
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Open	1.670
Previous Close	1.670
Day's Range	1.670 - 1.670
52-Week Range	1.670 - 3.250
Beta	-0.04
Analysts	n/a
Price Target	n/a
Est. Earnings	Nov 27, 2026

About ME Therapeutics Holdings

ME Therapeutics Holdings Inc., a preclinical stage biotechnology company, engages in the development of cancer fighting drugs in the field of immuno-oncology. The company’s lead candidate, h1B11-12, is a glycoprotein cytokine antibody drug that targets a key protein involved in the generation of suppressive myeloid cells for the treatment of colorectal cancer. It also develops D094 and D099, which are small molecule myeloid targeted prodrug candidates to treat cancer; and myeloid targeting lipid nanoparticles (LNPS) formulations. ME Therapeutic...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2014
• Country: Canada
• Stock Exchange: OTCMKTS
• Ticker Symbol: METXF

Financial Performance

Financial numbers in CAD

Data Sources: S&P Global Market Intelligence and Twelve Data

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Twelve Data.

Last checked:

Sep 25, 2026

Data Sources Report a data error